Exchange: NASDAQ·Updated 05:36 PM EDT
CGEN logo

CGENCompugen Ltd

$2.04
$0.05
(2.42%)
Today
Closed $2.02
$0.02
(0.99%)
After Hours
EarningsAug 5
Mkt Cap$195.73M
Vol268,881.00
News
all
press releases
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress PR Newswire HOLON, Israel, June 18, 2026...
PR Newswire
News Placeholder
More News
News Placeholder
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 PR Newswire HOLON, Israel, June 11, 2026 HOLON, Israel, June 11, 2026...
PR Newswire
News Placeholder
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development PR Newswire HOLON, Israel, June 8, 2026 HOLON, Israel, June 8, 2026 /PRNewswire...
PR Newswire
News Placeholder
Compugen Q1 2026 Earnings Call: Complete Transcript
read more...
Benzinga
News Placeholder
Compugen Q1 Earnings Call Highlights
Compugen Q1 Earnings Call Highlights...
Yahoo! Finance: News
News Placeholder
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of -9.14% and -16.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Compugen Reports First Quarter 2026 Results
Compugen Reports First Quarter 2026 Results Compugen Reports First Quarter 2026 Results PR Newswire HOLON, Israel, May 18, 2026 COM701 MAIA-ovarian trial actively enrolling patients across all...
PR Newswire
News Placeholder
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +8.48% and -28.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates
Adherex Technologies (FENC) delivered earnings and revenue surprises of +157.14% and +8.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum PR Newswire HOLON, Israel, May 12, 2026 HOLON, Israel...
PR Newswire
<
1
2
...
>

Advertisement|Remove ads.